463 patents
Page 11 of 24
Utility
DNA2 Inhibitors for Cancer Treatment
17 Feb 22
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 29 Oct 21
Utility
Meditopes and meditope-binding antibodies and uses thereof
15 Feb 22
Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
Filed: 5 Jun 17
Utility
Baff-r Antibodies and Uses Thereof
10 Feb 22
Provided herein are BAFF-R antibodies as well as compositions and methods of making and using the same.
Hong QIN, Larry W. KWAK, Jingxing LI, Kexin HUANG
Filed: 16 Aug 21
Utility
Truncated Epiderimal Growth Factor Receptor (EGFRt) for Transduced T Cell Selection
10 Feb 22
A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein.
Michael C. Jensen
Filed: 22 Oct 21
Utility
Compositions and methods for the treatment of hypercholesterolemia
8 Feb 22
Provided herein are, inter alia, compositions and methods for the treatment of hypercholesterolemia.
Kevin V. Morris, Roslyn Ray
Filed: 2 Feb 18
Utility
DNA methylation diagnostic test for breast cancer
8 Feb 22
The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.
Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu, Sun-Wing T. R. Tong
Filed: 28 Dec 18
Utility
Conditioning Regimens and Methods for Inducing Mixed Chimerism
3 Feb 22
Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells.
Defu ZENG
Filed: 11 Aug 21
Utility
RNA aptamers against transferrin receptor (TFR)
1 Feb 22
Provided herein, inter alia, are nucleic acid compounds capable of binding transferrin receptor on a cell and internalizing into said cell.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 15 Oct 15
Utility
Compound for Treating Cancer and Diabetes
27 Jan 22
One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.
Samuel RAHBAR, James L. FIGAROLA, Christopher LINCOLN, David HORNE, Rachael MOONEY, Monika POLEWSKI, George SOMLO, Lixin YANG, Sanjay AWASTHI, Sharad SINGHAL, Jyotasana SINGHAL
Filed: 6 Nov 17
Utility
Synthesis of ETP derivatives
25 Jan 22
David Horne, Jun Xie
Filed: 22 May 18
Utility
Chimeric antigen receptors containing a chlorotoxin domain
25 Jan 22
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes chlorotoxin or a related toxin, or a variant of chlorotoxin or a related toxin, that binds to human glioma or other human tumor cells, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Michael Barish, Christine E. Brown, Stephen J. Forman, Dongrui Wang
Filed: 13 Oct 16
Utility
Nanoparticles for Cancer Detection
20 Jan 22
Disclosed herein, inter alia, are methods for detecting cancer using nanoparticles.
Tom HABER, Pengpeng CAO, Jacob BERLIN, Karen ABOODY
Filed: 23 Aug 21
Utility
P38 map kinase inhibitors
18 Jan 22
Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors.
John J. Rossi, Sorah Yoon
Filed: 15 Jun 20
Utility
Baff-r Targeted Chimeric Antigen Receptor-modified T-cells and Uses Thereof
13 Jan 22
Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R).
Hong QIN, Larry W. KWAK
Filed: 3 Sep 21
Utility
Bi-specific aptamer
11 Jan 22
Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 17 Feb 17
Utility
Parg Inhibitors and Method of Use Thereof
6 Jan 22
Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.
Xiaochun Yu, Shih-Hsun Chen, Yate-Ching Yuan, Hongzhi LI, David Horne
Filed: 22 Jun 18
Utility
Oligonucleotide Inhibitors of Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells and the Uses Thereof
6 Jan 22
Disclosed herein, inter alia, are oligonucleotide inhibitors of the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) signaling pathway and methods of use thereof.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski
Filed: 23 Aug 19
Utility
Thioindirubins
4 Jan 22
Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.
Sangkil Nam, David Horne, Ravi Salgia, Alexios Leandros Skaltsounis, Nicolas Gaboriaud-Kolar, Panagiotis Gerolymatos, Nikolaos Lougiakis
Filed: 30 Aug 18
Utility
Methods and compositions for the treatment of cancer or other diseases
28 Dec 21
The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases.
Hua Yu, Marcin Kortylewski, Richard Jove, Piotr Marek Swiderski, John J. Rossi
Filed: 6 Mar 19
Utility
Recombinant Lectin and Uses Thereof
23 Dec 21
Disclosed herein are a recombinant Streptomyces S27S5 hemagglutinin (SHA), and homologues thereof, and a fusion protein of a fluorescent protein (such as GFP and mCherry1) and SHA or a homologue thereof, which specifically bind to carbohydrates, including oligomeric sugars that terminate in L-rhamnose or D-galactose.
Markus KALKUM, Yoko FUJITA-YAMAGUCHI, Karine BAGRAMYAN, Teresa B. HONG, Sarah SHUCK
Filed: 4 Aug 21